Abuse liability assessment of an electronic cigarette in combustible cigarette smokers.

Autor: Maloney SF; Department of Psychology, College of Humanities and Sciences, Virginia Commonwealth University., Breland A; Department of Psychology, College of Humanities and Sciences, Virginia Commonwealth University., Soule EK; Department of Psychology, College of Humanities and Sciences, Virginia Commonwealth University., Hiler M; Department of Psychology, College of Humanities and Sciences, Virginia Commonwealth University., Ramôa C; Department of Psychology, College of Humanities and Sciences, Virginia Commonwealth University., Lipato T; Department of Internal Medicine, Division of General Internal Medicine, Virginia Commonwealth University., Eissenberg T; Department of Psychology, College of Humanities and Sciences, Virginia Commonwealth University.
Jazyk: angličtina
Zdroj: Experimental and clinical psychopharmacology [Exp Clin Psychopharmacol] 2019 Oct; Vol. 27 (5), pp. 443-454. Date of Electronic Publication: 2019 Feb 18.
DOI: 10.1037/pha0000261
Abstrakt: Under certain conditions, electronic cigarettes (e-cigs) can deliver nicotine to and suppress tobacco abstinence symptoms in cigarette smokers. Growing popularity of e-cigs raises abuse liability concerns. This study's purpose was to compare the abuse liability of an e-cig (1.5 Ohm, 3.3 V) filled with 36 mg/mL or 0 mg/mL nicotine to an Food and Drug Administration (FDA)-approved nicotine inhaler (IN) and participants' own brand (OB) of cigarettes. Smokers (N = 24) completed four sessions in which they completed the multiple-choice procedure, and plasma nicotine concentration and subjective effects were measured. Mean (SD) multiple-choice procedure crossover point was $0.87 (1.0) for the 36-mg/mL nicotine e-cig and $0.96 (1.2) for the 0-mg/mL e-cig, significantly higher than the IN mean of $0.32 (0.6) but significantly lower than the OB cigarette mean of $1.42 (1.4). Ten puffs from an own-brand cigarette increased mean plasma nicotine concentration from 3.55 (2.8) to 13.64 (9.8) ng/mL, as compared to an increase from 3.16 (1.8) to 8.51 (5.4) ng/mL for the 36-mg/mL e-cig. The 36-mg/mL e-cig reduced nicotine abstinence symptoms more than the 0-mg/mL e-cig, and both e-cigs were rated as more reinforcing than the inhaler but less reinforcing than participants' OB cigarettes (ps < .05). Results suggest that the e-cig examined had higher abuse liability than the IN but lower than combustible cigarettes. These data and methods may be useful for policymakers by revealing how e-cig abuse liability compares to tobacco/nicotine products with abuse liability profiles that are well established. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
Databáze: MEDLINE